Brain Reaction to Treatment of Nicotine Dependence
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00108173 |
Recruitment Status
:
Completed
First Posted
: April 15, 2005
Last Update Posted
: April 9, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of the study was to determine how the treatments for cigarette craving work.
Hypothesis: During exposure to cigarette-related cues, heavy smokers will have greater reductions in regional brain activation from before to after both forms of active treatments than from before to after placebo.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Nicotine Dependence | Drug: Zyban | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 104 participants |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Neural Substrates of Treatment for Nicotine Dependence |
Study Start Date : | October 2002 |
Actual Primary Completion Date : | April 2007 |
Actual Study Completion Date : | June 2011 |
Arm | Intervention/treatment |
---|---|
Arm 1 | Drug: Zyban |
- 2-FA PET scan results [ Time Frame: Within the first few weeks of study initiation ]Brain activity and activation in response to cigarette-related cues

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Heavy smoker, more than one pack per day
- Free of medical conditions or medications that affect brain activity
- Not pregnant
Exclusion Criteria:
Drug or alcohol dependence Mental Illness Pregnancy Medications that affect brain function Unstable medical conditions

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00108173
United States, California | |
VA Greater Los Angeles Healthcare System, West LA | |
West Los Angeles, California, United States, 90073 |
Principal Investigator: | Arthur L. Brody, MD | VA Greater Los Angeles Healthcare System, West LA |
Responsible Party: | VA Office of Research and Development |
ClinicalTrials.gov Identifier: | NCT00108173 History of Changes |
Other Study ID Numbers: |
ADRD-018-02S |
First Posted: | April 15, 2005 Key Record Dates |
Last Update Posted: | April 9, 2013 |
Last Verified: | April 2013 |
Keywords provided by VA Office of Research and Development:
Position Emission Tomography (PET) Nicotine dependence functional magnetic resonance imaging cigarette cues |
Additional relevant MeSH terms:
Tobacco Use Disorder Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Nicotine Ganglionic Stimulants Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Nicotinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |